Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference
October 19 2016 - 5:30AM
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy
developer, today announced that its Chief Executive Officer, Dr.
Mark Heffernan, is scheduled to present at the 25th Annual Credit
Suisse Healthcare Conference in Scottsdale, AZ on Monday,
November 7th at 11:00AM MT.
Dr. Heffernan will provide an overview of Nexvet’s pivotal-stage
clinical programs for chronic pain in cats and dogs, as well as its
therapies in development in the areas of immuno-oncology,
inflammation, and allergy.
The presentation will be available on the investor section of
Nexvet's website at http://ir.nexvet.com following the completion
of the event.
About Nexvet
(www.nexvet.com)
Nexvet is a veterinary biologic therapeutics company focused on
transforming the therapeutic market for companion animals, such as
dogs and cats, by developing and commercializing novel,
species-specific biologics. Nexvet’s proprietary PETization™
platform is designed to rapidly design monoclonal antibodies (mAbs)
that are recognized as “self” or “native” by an animal’s immune
system, a property Nexvet refers to as “100% species-specificity.”
Nexvet’s product candidates build upon the safety and efficacy data
from clinically tested human therapies, thereby reducing clinical
risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to
build a vertically integrated biopharmaceutical company, which
conducts drug discovery in Australia, conducts clinical
development in the United States and Europe and conducts
biomanufacturing in Ireland.
Further information:
Investors
Candice
Knoll
Blueprint Life Science
Group
+1 415-375-3340 Ext.
4
cknoll@bplifescience.com
MediaJessica BurnsBerry & Company Public
Relations+1 212-253-8881jburns@berrypr.com
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Mar 2024 to Apr 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Apr 2023 to Apr 2024